Please login to the form below
Lamzede
This page shows the latest Lamzede news and features for those working in and with pharma, biotech and healthcare.
Chiesi launches new rare disease R&D division
Chiesi already markets rare disease therapy Lamzede (velmanase alfa), which is approved by the European Medicines Agency for the treatment of patients with mild to moderate alpha-mannosidosis. ... Chiesi acquired Lamzede when it bought Zymenex in 2013
Latest news
-
Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more
England’s cost effectiveness watchdog NICE has published draft guidance not recommending Chiesi’s enzyme replacement therapy Lamzede (velmanase alfa).
-
Chiesi's ultra-rare genetic disorder therapy wins European backing
Chiesi Group’s Lamzede (velmanase alfa) has been recommended for approval in Europe, putting it on course to become the first pharmacological therapy to reach the market for Alpha-Mannosidosis (AM). ... Lamzede, which was acquired when the Italian
-
NICE backs Europe's first stem cell therapy
be joined by Lamazym/Lamzede (velmanase alfa), used as an enzyme replacement therapy for the genetic disorder alpha-mannosidosis which is currently under review in Europe.
Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more
Chiesi's ultra-rare genetic disorder therapy wins European backing
NICE backs Europe's first stem cell therapy
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Medical Writer
-
Competitive Salary
-
Publications Director
-
Competitive Salary
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Account Manager
-
Competitive Salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
-
Medical Editor
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
-
Account Management
-
Competitive Salary Offered
-
Associate Account Director
-
Competitive Salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Senior Account Executive
-
Competitive Salary
- Merck & Co reveals plans for women’s health spinoff Organon
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- bluebird bio aiming to separate business units by year-end
- FDA accepts BMS’ investigational cardiovascular drug mavacamten for review
- Single dose of COVID-19 vaccines ‘significantly’ reduces infections
- Pfizer asks UK's MHRA to approve its COVID-19 vaccine in adolescents
- Clark Health promotes Siân Hurst to managing director role
- ENGINE MHP+Mischief bolsters healthcare comms expertise with new senior hires
- New court filing alleges Sanofi destroyed emails relating to Zantac recall
- Pfizer warns that IP waiver for COVID-19 vaccines may invite ‘copycat medicines’
- EMA introduces new measures to enable flexibility for non-COVID-19 procedures
- Pfizer asks UK's MHRA to approve its COVID-19 vaccine in adolescents
- New court filing alleges Sanofi destroyed emails relating to Zantac recall
- Merck & Co reveals plans for women’s health spinoff Organon
- Virtual agency The Difference Collective makes new hires to senior team
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- The impact of cancer on mental health during COVID-19
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
